Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
The investigators will test the central hypothesis that DFO treatment after SAH may improve
 cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective
 neuroprotectant against delayed ischemic injury after SAH.
Inclusion Criteria:

 -  diagnosis of spontaneous SAH

 -  impaired cerebral autoregulation on day 2-4 post SAH

 Exclusion Criteria:

 -  traumatic SAH

 -  other central neurological disorders such as tumors, known prior stroke, hemorrhage or
 vascular malformations

 -  pregnancy

 -  severe renal disease or anuria